Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy

J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e501-e503. doi: 10.1111/jdv.17232. Epub 2021 Mar 28.

Authors

R Maglie¹, F Ugolini², F De Logu³, S Simi², S Senatore¹, F Montefusco¹, R Nassini³, D Massi², E Antiga¹

Affiliations

¹ Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
² Department of Health Sciences, Section of Pathological Anatomy, University of Florence, Florence, Italy.
³ Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

PMID: 33730368
DOI: 10.1111/jdv.17232

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Hematologic Neoplasms*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell*
Skin Diseases*

Substances

Antibodies, Monoclonal, Humanized
dupilumab